JANX:NASDAQJanux Therapeutics, Inc. Analysis

Janux Therapeutics (JANX) trades at $14.03, barely above its technical support of $13.585 and well below its 200‑day SMA of $19.14, indicating a price lagging long‑term momentum. The 20‑day SMA sits just above the 50‑day SMA (14.56 vs 14.42), but both are under the long‑term trend line, while a bearish MACD histogram (‑0.078) and a neutral RSI (42.9) suggest limited upside in the near term. Volatility is elevated at 31.8% over the past 30 days and beta is around 1.3, implying the stock moves more sharply than the market.
Fundamentally, JANX carries a massive cash cushion of $956 M against modest debt ($21.5 M) yet generates negative operating and free cash flow, with a PE of –5.06 and a price‑to‑sales ratio of 62×, flagging severe valuation stretch. The company’s pipeline setback – the discontinuation of JANX008 – and recent analyst actions (Barclays downgrade to Underweight, BofA target cut to $24) add headwinds, while the consensus “strong buy” rating and a median price target of $37 suggest a long‑run upside of roughly 150‑200% if clinical milestones are achieved.